Evidence map›Paper›PMID 42022590›Full record

ArticleChronic diseases and translational medicine2026

The Promoting Angiogenesis and Its Clinical Significance of CD33

Heran Cui, Jingjing Liu, Peiyan Zhao, Yan Liu, Shaowei Lan, Xueli Jiang, Hui Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chronic diseases and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heran CuiBiobank, Jilin Cancer Hospital, Changchun Jilin China.
Jingjing LiuBiobank, Jilin Cancer Hospital, Changchun Jilin China.
Peiyan ZhaoTranslational Oncology Research Lab, Jilin Province and Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun Jilin China.ORCID https://orcid.org/0000-0002-6977-339X
Yan LiuTranslational Oncology Research Lab, Jilin Province and Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun Jilin China.
Shaowei LanTranslational Oncology Research Lab, Jilin Province and Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun Jilin China.
Xueli JiangBiobank, Jilin Cancer Hospital, Changchun Jilin China.
Hui LiBiobank, Jilin Cancer Hospital, Changchun Jilin China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Myeloid-derived suppressor cells (MDSCs) are important tumor microenvironment components in small cell lung cancer (SCLC). We successfully identified MDSCs expressing the surface marker CD33 in SCLC; nonetheless, whether CD33 Method: Nineteen patients diagnosed with extensive-stage SCLC at Jilin Cancer Hospital were selected as the research subjects. CD33 Results: Compared to healthy individuals, the CD33 Conclusion: CD33

Indexed as

angiogenesismyeloid derived suppressor cellsprognosissmall cell lung cancertherapeutic effect

Identifiers

PMID42022590
PMCPMC13097379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.